Business
Mdxhealth Reports Preliminary Second Quarter 2025 Results, Reaches Positive Adjusted EBITDA, and Announces Acquisition of Exosome Diagnostics Business from Bio-Techne
Mdxhealth Reports Preliminary Second Quarter 2025 Results, Reaches Positive Adjusted EBITDA, and Announces Acquisition of Exosome Diagnostics Business from Bio-Techne Year-over-year Q2 revenues increased by 20% to $26.6 millionAdjusted EBITDA profitability of $1.4 million for Q2 Agreement to acquire ExoDx Business from Bio-Techne for $15 million in cash and stock over 5 years; acquisition expected to accelerate revenue growth and be accretive to adjusted EBITDA Conference call with Q&A today at
About this update from Mdxhealth Sa
[{"type":"image","alt":"mdxhealth","displaySize":"","headline":null,"caption":"mdxhealth","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":44,"url":"https://media.zenfs.com/en/globenewswire.com/4984d0922515a173e18d6d7a99b017cc"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Sf2Nm0vg.EDhfYYAQ2giIg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTYyO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/4984d0922515a173e18d6d7a99b017cc","width":300,"height":44}},"lazy":false},{"type":"text","content":"Mdxhealth Reports Preliminary Second Quarter 2025 Results, Reaches Positive Adjusted EBITDA, and Announces Acquisition of Exosome Diagnostics Business from Bio-Techne","length":166,"tagName":"p"},{"type":"text","content":"Year-over-year Q2 revenues increased by 20% to $26.6 millionAdjusted EBITDA profitability of $1.4 million for Q2","length":113,"tagName":"p"},{"type":"text","content":"Agreement to acquire ExoDx Business from Bio-Techne for $15 million in cash and stock over 5 years; acquisition expected to accelerate revenue growth and be accretive to adjusted EBITDA ","length":185,"tagName":"p"},{"type":"text","content":"Conference call with Q&A today at 4:30 PM ET / 22:30 CET","length":60,"tagName":"p"},{"type":"text","content":"IRVINE, CA, and HERSTAL, BELGIUM – August 5, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced preliminary financial results for the second quarter and half year ended June 30, 2025. The Company also announced that it has entered a definitive agreement to acquire the ExoDx business from Bio-Techne Corporation, which includes the ExoDx Prostate test.","length":461,"tagName":"p"},{"type":"text","content":"Michael K. McGarrity, CEO of mdxhealth, commented: “We are pleased to report our 17th consecutive quarter of 20% or greater revenue growth, driven by our continued execution and strong demand for our leading tissue-based tests, GPS and Confirm mdx. This quarter also marks a key milestone for mdxhealth, as we reached adjusted EBITDA profitability of $1.4 million for Q2, in line with our guidance since the beginning of 2024.","length":431,"tagName":"p"},{"type":"text","content":"We are also excited to announce that we have entered into a transformative agreement with Bio-Techne to acquire...